AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Dravet Syndrome

Recent research efforts aimed at curing Dravet Syndrome.

Last updated

Dravet Syndrome

Overview

Dravet syndrome is a rare, lifelong developmental and epileptic encephalopathy: a severe disorder in which early, often fever-triggered seizures are accompanied by developmental, cognitive, behavioral, motor, sleep, and autonomic difficulties. Seizures commonly begin during the first year of life in an apparently healthy infant. Most cases result from a loss-of-function variant in one copy of SCN1A, which lowers activity of the NaV1.1 sodium channel in inhibitory brain cells that normally restrain excessive electrical activity. The condition carries risks of prolonged seizures, injury, and sudden unexpected death in epilepsy (SUDEP), and many affected people need support throughout adulthood. International consensus

Current care aims to prevent seizures and manage complications rather than correct the underlying genetic cause. Standard care includes individualized antiseizure combinations—often valproate and clobazam, with condition-specific add-on options such as stiripentol, fenfluramine, or pharmaceutical cannabidiol—plus rescue medication plans, avoidance of known triggers, developmental therapies, and consideration of dietary or device-based treatments in selected patients. These approaches can substantially reduce seizures for some people, but they do not reliably prevent the broader developmental effects of Dravet syndrome or constitute a cure. International consensus

Scope of Recent Research (2020–present)

Research activity has accelerated markedly since 2020 because Dravet syndrome has a relatively clear biological target: restoring adequate NaV1.1 function in inhibitory neurons. The dominant questions are whether increasing output from the unaffected SCN1A copy can durably alter disease progression, whether one-time viral gene regulation can safely reach the right brain cells, and whether direct DNA correction can be delivered broadly enough to be practical. A first disease-targeting RNA therapy has now entered Phase 3 testing, while gene-regulation therapy is in Phase 1/2 and gene editing remains preclinical; therefore, the field is closer to disease modification than to a proven cure. Zorevunersen Phase 3 trial ETX101 ENDEAVOR trial

Major Breakthroughs and Emerging Therapies

The leading clinical approach is RNA therapy with zorevunersen (formerly STK-001), an antisense oligonucleotide—a short, synthetic strand of nucleic acid delivered by spinal injection. It blocks inclusion of a nonproductive “poison exon” in SCN1A RNA, allowing the unaffected copy of the gene to make more functional NaV1.1 protein. In a 2020 Dravet mouse study, this strategy increased Scn1a expression, reduced seizures and SUDEP-like mortality, and improved survival. Antisense therapy in Dravet mice In the subsequently reported Phase 1/2a and open-label extension studies in children and adolescents, zorevunersen was associated with durable seizure reductions and improvements in adaptive behavior measures, but these early studies were not blinded or sham-controlled and cannot yet prove a curative effect. Zorevunersen clinical study

A second root-cause strategy is cell-selective gene regulation. ETX101 is a one-time intracerebroventricular treatment using an adeno-associated virus serotype 9 (AAV9) vector. Rather than inserting a replacement SCN1A gene, it delivers an engineered transcription factor designed to increase production from the patient’s existing SCN1A gene preferentially in GABAergic inhibitory neurons. In Scn1a-deficient mice, the corresponding vector reduced generalized seizures and mortality, and nonhuman-primate experiments showed broad brain distribution after ventricular delivery. AAV9 SCN1A gene regulation

Direct gene replacement and editing are progressing in animal models. A 2020 study used CRISPR/dCas9 gene activation—an altered CRISPR system that turns a gene up without cutting DNA—to increase Scn1a in inhibitory neurons and improve seizures and behavior in Dravet-model mice. CRISPR gene activation More recently, researchers demonstrated interneuron-targeted, dual-AAV delivery of SCN1A gene replacement in mouse models, an important advance because the full SCN1A sequence is too large for a standard single AAV vector. Interneuron-specific SCN1A replacement In 2026, adenine base editing corrected a recurrent Dravet-causing SCN1A nonsense variant in mice and ameliorated disease features, providing a proof of concept for permanent, mutation-specific repair. In vivo adenine base editing

Small-molecule programs remain important for seizure control but should not be described as cures because they do not repair or normalize SCN1A. Examples include clemizole hydrochloride (EPX-100), a repurposed serotonin-pathway drug in the Phase 3 ARGUS study, and bexicaserin, a selective serotonin 5-HT2C receptor agonist in a Phase 3 Dravet study. Their value, if confirmed, would be as additional symptomatic or potentially disease-modifying seizure therapies alongside—not replacements for—genetic approaches. EPX-100 ARGUS trial Bexicaserin Phase 3 trial

Clinical Trials and Experimental Approaches

Zorevunersen is the most advanced SCN1A-targeted program. Stoke Therapeutics and Biogen’s global Phase 3 EMPEROR trial is randomized, double-blind, and sham-controlled; it tests intrathecal zorevunersen in people aged 2 to under 18 years with Dravet syndrome caused by an eligible non-gain-of-function SCN1A variant. Its primary outcome is change in major motor seizure frequency, with cognition, behavior, clinical status, and quality of life among key secondary outcomes. The sponsor announced on June 30, 2026 that enrollment of 162 participants had been completed; the registry lists primary completion in March 2027 and full study completion in October 2028. EMPEROR trial Enrollment announcement

Encoded Therapeutics’ ENDEAVOR study of ETX101 is a recruiting Phase 1/2 program for infants and children with SCN1A-positive Dravet syndrome. The first part uses open-label dose escalation; the second part uses a randomized, double-blind, sham-delayed-treatment design. It measures safety, seizure frequency, and developmental outcomes including Bayley and Vineland assessments. As of the June 10, 2026 registry update, no clinical results had been posted. ETX101 ENDEAVOR trial

Phase 3 studies of non-genetic adjunctive therapies are also underway. ARGUS evaluates EPX-100 in participants aged 2 years and older with Dravet syndrome, while the DEE-p SEA trial evaluates oral bexicaserin in children and adults with Dravet syndrome. These trials may expand seizure-control options, but neither is designed to correct the disease-causing DNA variant. EPX-100 ARGUS trial Bexicaserin Phase 3 trial

Methodologies and Scientific Approaches

Researchers combine genetically precise animal models, patient-derived cells, and early clinical biomarkers. Mouse models carrying Scn1a loss-of-function variants allow investigators to measure febrile seizures, spontaneous seizures, survival, behavior, and interneuron function after treatment. Nonhuman primates are used to assess the brain distribution and tolerability of viral vectors before pediatric trials. Human induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed into stem cells and then differentiated into neurons or three-dimensional brain organoids, provide a way to test patient-specific SCN1A variants and treatment effects in human neural tissue. AAV9 SCN1A gene regulation Dravet iPSC organoid model

Clinical development is increasingly designed to measure more than seizure counts. Current studies track major motor seizures alongside safety, drug exposure in cerebrospinal fluid, EEG measures, adaptive behavior, cognition, communication, motor skills, caregiver assessments, and quality of life. This broader approach reflects the central question for a potential cure: whether restoring NaV1.1 can change the developmental course of Dravet syndrome, not merely suppress seizures temporarily. Zorevunersen clinical study ETX101 ENDEAVOR trial

Leading Institutions and Funding

Clinical leadership is shared among specialist pediatric epilepsy centers and biotechnology companies. Zorevunersen’s studies include investigators at institutions such as Ann & Robert H. Lurie Children’s Hospital of Chicago, University of California San Francisco, Cook Children’s Medical Center, Mayo Clinic, University College London, and other international epilepsy centers; Stoke Therapeutics sponsors the program in collaboration with Biogen. Zorevunersen clinical study ETX101 is sponsored by Encoded Therapeutics, while preclinical SCN1A replacement and editing work includes groups at the Children’s Hospital of Philadelphia, the Broad Institute, Harvard University, and collaborating vector-development laboratories. In vivo adenine base editing Interneuron-specific SCN1A replacement

Patient-led funding is materially shaping the field. In 2024, the Dravet Syndrome Foundation awarded $1.4 million across five grants, including two $500,000 transformational grants for circuit-selective whole-SCN1A delivery and analysis of exogenous NaV1.1, plus a $250,000 grant to develop base editing for Dravet syndrome through a collaboration involving Children’s Hospital of Philadelphia and the Liu laboratory at MIT and Harvard. 2024 DSF grant awards

Strengths, Limitations, and Challenges

The field’s principal strength is a coherent, biologically grounded target: in most people with Dravet syndrome, one functional SCN1A copy remains available for upregulation. Zorevunersen has provided the strongest human signal to date because early-phase results included persistent seizure reductions and favorable developmental trends while patients continued standard treatment. However, the evidence remains preliminary: the key early studies were open-label, enrolled a limited number of participants, and lacked a concurrent blinded control group, so maturation, regression to the mean, and changes in background care cannot be fully excluded. Zorevunersen clinical study

Important safety and applicability questions remain. Zorevunersen requires repeated intrathecal dosing and has been associated with cerebrospinal-fluid protein elevations; its Phase 3 population excludes SCN1A gain-of-function variants, so it will not address every person with an SCN1A-related epilepsy. Zorevunersen Phase 3 trial AAV gene-regulation therapy may offer durable one-time treatment, but it requires neurosurgical delivery and must establish long-term dose control, durability, and safety in young children. Direct replacement and base editing may ultimately be more definitive for some variants, but they must overcome delivery to enough relevant neurons, potential unintended edits or gene-expression effects, and the challenge that each editing design may address only a subset of SCN1A variants. ETX101 ENDEAVOR trial In vivo adenine base editing

Outlook and Future Directions

Dravet syndrome is not yet curable, but 2020–2026 moved the field from promising animal rescue experiments to a pivotal Phase 3 test of an SCN1A-restoring RNA therapy and an ongoing Phase 1/2 AAV gene-regulation trial. The most important milestones to watch are the blinded EMPEROR results expected after its March 2027 primary-completion target, ETX101 safety and developmental data, and replication of gene-replacement and base-editing results across multiple variants and longer treatment windows. A near-term realistic goal is the first therapy that demonstrably modifies disease trajectory; a broadly applicable, durable genetic cure will require stronger controlled evidence, long-term follow-up, and solutions for variant diversity and brain-wide delivery. EMPEROR trial ETX101 ENDEAVOR trial

References

Don't see your disease? Request a report